Drug intelligence / Profile preview

Granprox

Development stage: Unknown
Lead developer: Kéri Pharma
Modality: Small Molecules
Administration: Oral

Overview

Granprox is a dietary supplement developed and marketed by Kéri Pharma Hungary, specifically formulated to support prostate and urinary tract health in men over 40 years of age. The product is an oral film-coated tablet containing a combination of 100% natural rye pollen extract (flower pollen extract) and a B-vitamin complex, including vitamins B2 (riboflavin), B3 (niacin), B6 (pyridoxine), and B12 (cyanocobalamin). The rye pollen extract is intended to help maintain healthy prostate and bladder function, while the B vitamins contribute to the normal functioning of the immune system and help reduce fatigue and exhaustion. Granprox is marketed as a gluten-free and GMO-free nutritional support product.

Brand names: Granprox
Other names: Granprox filmtabletta

Targets

ADRA1A (α1A)

Beyond the preview

Go deeper on Granprox.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Granprox.

Explore the full profile